{
    "id": "148hx7k",
    "score": 40,
    "title": "Immix Biopharma Subsidiary Nexcella Appoints Henry McKinnell, Jr., former Chairman &amp; CEO of Pfizer Inc., to Board of Directors",
    "author": "billerspinholds30",
    "date": 1686669833.0,
    "url": "https://www.reddit.com/r/StockMarket/comments/148hx7k",
    "media_urls": [],
    "other_urls": [],
    "postText": "Yo what's up Stock Market!!! Just stumbled upon some exciting news in the biopharmaceutical world and couldn't wait to share it with you all. So, there's this company called Nexcella, a subsidiary of Immix Biopharma, and they've just announced a major addition to their Board of Directors. Dr. Henry A. McKinnell, Jr., former Chairman and CEO of Pfizer has joined the team. Which is just massive news! \n\n**Summary:**\n\nThis is a significant development for Nexcella as it brings on board a seasoned pharmaceutical executive with vast experience in developing and launching drug candidates, forming alliances, and building world-class operations. The addition of Dr. McKinnell highlights Nexcella's commitment to advancing cell therapies, particularly their lead candidate NXC-201 for multiple myeloma and AL amyloidosis.\n\n**Highlighted Main Points:**\n\n1. Nexcella is a subsidiary of Immix Biopharma, focused on the discovery and development of novel cell therapies for oncology and other indications.\n2. Dr. McKinnell's appointment signifies Nexcella's commitment to advancing NXC-201, their lead candidate for multiple myeloma and AL amyloidosis, which has shown promising response rates in clinical trials.\n\n**TLDR:**\n\nThis move brings valuable expertise to Nexcella's efforts in developing cutting-edge cell therapies, particularly their lead candidate NXC-201 for multiple myeloma and AL amyloidosis! \n\n&amp;#x200B;",
    "comments": []
}